Skip to main content
Special Report
Unmeasured confounding in nonrandomized studies: quantitative bias analysis in health technology assessment
- Thomas P Leahy,
- Seamus Kent,
- Cormac Sammon,
- Rolf HH Groenwold,
- Richard Grieve,
- Sreeram Ramagopalan, and
- Manuel Gomes
pp851–859
Published Online:9 June 2022
Research Article
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling
- Thomas P Leahy,
- Stephen Duffield,
- Seamus Kent,
- Cormac Sammon,
- Dimitris Tzelis,
- Joshua Ray,
- Rolf HH Groenwold,
- Manuel Gomes,
- Sreeram Ramagopalan, and
- Richard Grieve
pp861–870
Published Online:9 June 2022
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China
- Xudong Zhang,
- Pingping Fang,
- Guangquan Su,
- Shuangying Gui, and
- Aizong Shen
pp871–878
Published Online:24 June 2022
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study
- Zhenbao Li,
- Jianwei Xuan,
- Xinggen Fang,
- Xintong Zhao,
- Bingbing Zhang,
- Degang Wu,
- Niansheng Lai,
- Jiaqiang Liu,
- Zihuan Zhang,
- Jinlong Yuan, and
- Feiyun Qin
pp879–887
Published Online:23 June 2022
Meta-Analysis
Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson’s disease: a systematic review and meta-analysis
- Magdalena Żegleń,
- Katarzyna Śladowska,
- Paweł Kawalec, and
- Tomasz Brzostek
pp889–904
Published Online:27 June 2022
Review
Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers
- Maria Kamusheva,
- Bertalan Németh,
- Antal Zemplényi,
- Zoltán Kaló,
- Jamie Elvidge,
- Maria Dimitrova,
- Johan Pontén,
- Konstantin Tachkov, and
- Zornitsa Mitkova
pp905–913
Published Online:21 June 2022